Psychedelic drug

HealingMaps Announces New Advisory Board and Team Members, Participation in MAPS Psychedelic Science Conference

Retrieved on: 
Friday, June 16, 2023
The Washington Post, Raigam Tele'es Best Television News Reader Award, MBA, Ibogaine, Veteran, Multidisciplinary Association for Psychedelic Studies, Foundation (nonprofit), MAPS, Developed country, ROI, Mental health, Conference, TIAS School for Business and Society, Third wave, Nightclub, Pharmaceutical industry, Wikimedia Foundation, Psychedelic drug

Miami, Florida--(Newsfile Corp. - June 16, 2023) - HealingMaps Inc. ("HealingMaps") the world's most informative and trusted psychedelic therapy search site, is pleased to announce the addition of renowned members to its advisory board and team and its participation in the highly anticipated MAPS Psychedelic Science Conference.

Key Points: 
  • Miami, Florida--(Newsfile Corp. - June 16, 2023) - HealingMaps Inc. ("HealingMaps") the world's most informative and trusted psychedelic therapy search site, is pleased to announce the addition of renowned members to its advisory board and team and its participation in the highly anticipated MAPS Psychedelic Science Conference.
  • HealingMaps is excited to welcome Toby Negrin to its advisory board.
  • HealingMaps is pleased to announce its involvement in Psychedelic Science 2023, the breakthrough conference hosted by Multidisciplinary Association for Psychedelic Studies (MAPS).
  • "I'm thrilled to introduce our new team members as we gear up for Psychedelic Science 2023 and beyond," said HealingMaps CEO, Cory Jones.

Psychedelic Science 2023 Announces Final Agenda, Additional Featured Speakers, and Special Local Day Pass Option

Retrieved on: 
Tuesday, June 13, 2023
Momentum, Katherine, Toms Shoes, Stanford School, Catherine Oxenberg, Exhibition, Education, Culture, Shoe, Policy, Psychedelic drug, IOS, Multidisciplinary Association for Psychedelic Studies, Stanford University School of Medicine, MAPS, Google Play, Conference, Neuroscientist, Shoemaking, Nightclub, Neuroscience

DENVER, June 13, 2023 (GLOBE NEWSWIRE) -- Psychedelic Science 2023, the breakthrough psychedelic conference hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced it has released the final agenda including additional featured speakers and a new Friday Local Day Pass option for the world’s most compelling conference within the psychedelic ecosystem, taking place June 19-23, 2023 in Denver, Colorado.

Key Points: 
  • With an estimated 10,000 attendees, the Psychedelic Science 2023 agenda will feature five days of panels, workshops, and lectures from leaders and visionaries in psychedelic research, education, policy, business, culture, and communities.
  • Conference tracks will be complemented by pre-conference workshops; an exhibit hall; and an interactive installation space featuring artists, musicians, and other vendors from around the world.
  • Interested individuals will be eligible to purchase a one-day conference registration to attend the conference on Friday, June 23rd.
  • Local day passes will be available beginning Tuesday, June 13th and can be purchased at PsychedelicScience.org .

PharmCon freeCE Introduces “freeCE FREE Trial” Membership: Free Three-Credit Access to Its Most Popular CE Content

Retrieved on: 
Tuesday, June 13, 2023
CE, Pharmacy, FREE, Psychedelic drug, Highs, Silver, Nursing, CBD, Monograph, Haze, Pharmacy technician, Dietary supplement, Uncertainty, Pharmacist, Gold

RADNOR, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- PharmCon freeCE, a division of KnowFully Learning Group and a leading provider of live online continuing education (CE), today introduced the “freeCE FREE Trial,” a membership that gives users completely free access to three credits of the company’s best CE content.

Key Points: 
  • RADNOR, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- PharmCon freeCE, a division of KnowFully Learning Group and a leading provider of live online continuing education (CE), today introduced the “freeCE FREE Trial,” a membership that gives users completely free access to three credits of the company’s best CE content.
  • “PharmCon freeCE is continually focused on making CE content as affordable, simple, and flexible as possible,” said Kevin Hope, senior director of pharmacy education for PharmCon freeCE.
  • The library will include five to seven courses that are applicable to all pharmacy professionals, including pharmacists, technicians, and nurses.
  • “We are cognizant that affordability is vital to the pharmacy tech community and are excited to make this content even more approachable.”

USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States

Retrieved on: 
Friday, June 9, 2023
Psilocybin, US Foods, Partnership, CSE, Authorization, USFDA, IMP, Clinical trial, ASX, Research, Psychedelic drug, Capsule, Documentation, DEA, Patient, OTC, Control, UCLA, FDA, Health Canada, Conference, MDMA, Food, Pharmaceutical industry, MDXX, Chemistry

VANCOUVER, British Columbia, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA)(OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules (including MDMA), is pleased to report that the US Food and Drug Administration (USFDA) has approved a clinical trial utilizing PharmAla’s LaNeo MDMA Investigational Medical Product (IMP) capsules (40mg). This is the first time that PharmAla’s IMP has been approved for trial use in the United States.

Key Points: 
  • This is the first time that PharmAla’s IMP has been approved for trial use in the United States.
  • “As with any IMP supplier, there are always questions about Chemistry, Manufacturing and Control - even for well-known molecules.
  • PharmAla supports numerous researchers around the world who are studying MDMA for a diverse series of indications.
  • “As with all of our clients, we worked hard to support UCLA Researchers in their application to USFDA.

PharmAla Awarded Research Grant by Ontario Centre for Innovation

Retrieved on: 
Friday, June 9, 2023
US Foods, CSE, University, Therapy, Drug discovery, UAMS, USFDA, MDXX, Innovation, Medicine, Psychedelic drug, Patient, Clinical research, OTC, Ontario Centre of Forensic Sciences, OCI, Conference, MDMA, Food, Pharmaceutical industry, Research

TORONTO, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA)(OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is excited to announce that it has been granted a research grant by the Ontario Centre for Innovation in conjunction with the University of Windsor.

Key Points: 
  • TORONTO, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA)(OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is excited to announce that it has been granted a research grant by the Ontario Centre for Innovation in conjunction with the University of Windsor.
  • PharmAla believes that this can be done through the aid of in-silico modelling.
  • To do that, our research team encompasses a diverse group of scientists: Preclinical researchers completing animal model research, In-Silico Drug Discovery, and very soon, Clinical Research,” said Nick Kadysh, CEO, PharmAla Biotech.
  • “The OCI grant will allow us to bolster the funnel of our drug pipeline and develop valuable IP with non-dilutive funding.

PSYC’s Psychedelic Spotlight Continues Ascent as a Top-Ranking Multimedia Platform for the Psychedelics Sector

Retrieved on: 
Tuesday, June 6, 2023
OTC Markets Group, Marketing, Google Analytics, Multimedia, Psychedelic drug, SEO, Management, Growth, Environment, News, Content, Mobile phone, Nightclub

Our commitment extends beyond content creation, as we have implemented a diverse range of SEO strategies, seamlessly integrated multimedia elements, and optimized website performance.

Key Points: 
  • Our commitment extends beyond content creation, as we have implemented a diverse range of SEO strategies, seamlessly integrated multimedia elements, and optimized website performance.
  • We believe the results speak for themselves, as Psychedelic Spotlight has ascended in both global and industry rankings.
  • However, what we think truly sets us apart is the significant growth we witnessed in our direct search traffic.
  • This remarkable surge indicates that our brand is achieving widespread recognition, garnering user loyalty, and establishing a strong brand identity.”

FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board

Retrieved on: 
Friday, June 2, 2023
Drug, BLUE, Multidisciplinary Association for Psychedelic Studies, ALL, Biotechnology, LSD, Attention, Psychedelic drug, Post-traumatic stress disorder, Research, FDA, Letter, Second Half, MDMA, PTSD, MindMed, FCM, Pharmaceutical industry, Management, Compass

SHERIDAN, Wyo., June 02, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC (“FCM”), published an open letter to the shareholders of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (“MindMed”, the “Company”) from MindMed’s co-founder Dr. Scott Freeman. The letter highlights Dr. Freeman’s prediction that a revolution in psychedelic medicine will likely occur by the end of 2024, heralded by the FDA’s likely approval of Multidisciplinary Association for Psychedelic Studies’ (“MAPS”) drug, MDMA, for post-traumatic stress disorder (PTSD).

Key Points: 
  • Dr. Freeman emphasizes his belief that for MindMed to be able to fully participate in the coming psychedelic medicine revolution it must have a healthy balance sheet.
  • FCM believes that by cutting costs and doubling-down MindMed’s investment in its flagship drug LSD (MM-120) this is achievable.
  • It is critical that MindMed be fully prepared to be part of this revolution and the increased potential value and opportunities in the psychedelic industry.
  • In contrast, FCM has budgeted an estimated $39 million in annual operating expenses by keeping MindMed lean and efficient.

World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board

Retrieved on: 
Tuesday, May 30, 2023
IHL, Clarion, Benzodiazepine, California Institute for Regenerative Medicine, Johns Hopkins School of Medicine, California Institute of Integral Studies, Caffeine, Psychedelic drug, Johns Hopkins University, Patient, Principal, Psilocybin, Emergency medicine, GHB, Principal investigator, Research, Private practice, Certification, Terminal, Cocaine, Psychedelic therapy, The MINDS Foundation, Psychiatry, Cannabis, Addiction, MDA, DPT, NIH, PTSD, Depression, Sunstone, DSM-IV codes, LSD, Alcoholism, Advisory board, Ketamine, Johns Hopkins Center for Health Security, Behavioural sciences, Johns Hopkins, Economics, Yoga, Methamphetamine, ASX, Consciousness, Trust, CQD, Dextromethorphan, Medical director, Episode, MDMA, Pharmaceutical industry, Nursing

MELBOURNE, Australia, May 30, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a pharmaceutical company developing proprietary drugs which use cannabis as an ingredient for unmet medical needs, psychedelic-assisted psychotherapy protocols, and an operator of psychedelic-assisted psychotherapy clinics, is pleased to announce that three of the world’s top psychedelic therapy and science experts have joined the Advisory Board of Clarion Clinics Group.

Key Points: 
  • Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.
  • The company is delighted to announce that, in addition to the most experienced psychedelics professionals in Australia taking key executive roles and directorships in the Clarion Clinics Group, three of the world’s most experienced and leading clinical psychedelic experts have joined its Advisory Board.
  • Andrea serves as the Medical Director of the OVID Clinics in Berlin, and is a co-founder and advisory board member of the MIND Foundation.
  • I’m grateful for their trust and support.”
    Peter Widdows, Incannex Director, said: “I’m delighted and honoured that such esteemed professionals have decided to join the Clarion Clinics team.

Icaro Connect, First Psychedelics Marketing and Advertising Company of Its Kind, Officially Launches New Website and Services

Retrieved on: 
Tuesday, May 30, 2023
Psilocybin, Advertising, Marketing, Entheogen, Psychedelic drug, Cannabis, Ketamine, HSO, PR, Nightclub

AUSTIN, Texas, May 30, 2023 /PRNewswire-PRWeb/ -- Icaro Connect, the first entheogenic, psychedelics marketing and advertising company, officially launched its updated website and services today - http://www.icaroconnect.com. Based in Austin, Texas, the company has been working with entheogen therapists, psychedelic shamans, dispensaries, labs, clinics, and more. The founders, Clif Haley and Carson Barker, saw the need for psychedelics marketing when the industry was in its infancy, and created the company to assist business growth, client expansion, and sales.

Key Points: 
  • AUSTIN, Texas, May 30, 2023 /PRNewswire-PRWeb/ -- Icaro Connect, the first entheogenic, psychedelics marketing and advertising company , officially launched its updated website and services today - http://www.icaroconnect.com .
  • Based in Austin, Texas, the company has been working with entheogen therapists, psychedelic shamans, dispensaries, labs, clinics, and more.
  • Icaro Connect uses customized services and industry knowledge to navigate clients through their business growth cycle safely and successfully.
  • "When we first ventured into psychedelics marketing, it felt like when we launched the first app marketing company, APPSPIRE.me, in 2009," said Barker.

Have a Good Trip Benefit Show to Celebrate MAPS and Psychedelic Medicine

Retrieved on: 
Thursday, May 18, 2023
Music, Mission Ballroom, Education, Multidisciplinary Association for Psychedelic Studies, Psychedelic drug, Have a Good Trip: Adventures in Psychedelics, MAPS, The Flaming Lips, AEG, Netflix, Nightclub

This once-in-a-lifetime event will feature performances by comics Eric Andre and Reggie Watts, followed by a full set of music by psychedelic rock band The Flaming Lips.

Key Points: 
  • This once-in-a-lifetime event will feature performances by comics Eric Andre and Reggie Watts, followed by a full set of music by psychedelic rock band The Flaming Lips.
  • The event is open to the public but will take place during Psychedelic Science 2023 , the breakthrough psychedelic conference hosted by MAPS.
  • More information about Psychedelic Science 2023 programming in sessions, themes, and event programming can be found here .
  • Good Trip Studios and AEG Rockies are making presale tickets available to all registered attendees of the conference beginning today, Thursday, May 18th.